Literature DB >> 20805624

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Deepak L Bhatt1, Kim A Eagle, E Magnus Ohman, Alan T Hirsch, Shinya Goto, Elizabeth M Mahoney, Peter W F Wilson, Mark J Alberts, Ralph D'Agostino, Chiau-Suong Liau, Jean-Louis Mas, Joachim Röther, Sidney C Smith, Geneviève Salette, Charles F Contant, Joseph M Massaro, Ph Gabriel Steg.   

Abstract

CONTEXT: Clinicians and trialists have difficulty with identifying which patients are highest risk for cardiovascular events. Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear.
OBJECTIVE: To categorize the risk of cardiovascular events in stable outpatients with various initial manifestations of atherothrombosis using simple clinical descriptors. DESIGN, SETTING, AND PATIENTS: Outpatients with coronary artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for atherothrombosis were enrolled in the global Reduction of Atherothrombosis for Continued Health (REACH) Registry and were followed up for as long as 4 years. Patients from 3647 centers in 29 countries were enrolled between 2003 and 2004 and followed up until 2008. Final database lock was in April 2009. MAIN OUTCOME MEASURES: Rates of cardiovascular death, myocardial infarction, and stroke.
RESULTS: A total of 45,227 patients with baseline data were included in this 4-year analysis. During the follow-up period, a total of 5481 patients experienced at least 1 event, including 2315 with cardiovascular death, 1228 with myocardial infarction, 1898 with stroke, and 40 with both a myocardial infarction and stroke on the same day. Among patients with atherothrombosis, those with a prior history of ischemic events at baseline (n = 21,890) had the highest rate of subsequent ischemic events (18.3%; 95% confidence interval [CI], 17.4%-19.1%); patients with stable coronary, cerebrovascular, or peripheral artery disease (n = 15,264) had a lower risk (12.2%; 95% CI, 11.4%-12.9%); and patients without established atherothrombosis but with risk factors only (n = 8073) had the lowest risk (9.1%; 95% CI, 8.3%-9.9%) (P < .001 for all comparisons). In addition, in multivariable modeling, the presence of diabetes (hazard ratio [HR], 1.44; 95% CI, 1.36-1.53; P < .001), an ischemic event in the previous year (HR, 1.71; 95% CI, 1.57-1.85; P < .001), and polyvascular disease (HR, 1.99; 95% CI, 1.78-2.24; P < .001) each were associated with a significantly higher risk of the primary end point.
CONCLUSION: Clinical descriptors can assist clinicians in identifying high-risk patients within the broad range of risk for outpatients with atherothrombosis.

Entities:  

Mesh:

Year:  2010        PMID: 20805624     DOI: 10.1001/jama.2010.1322

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  165 in total

1.  Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

Authors:  In-Suk Kim; Young-Hoon Jeong; Yongwhi Park; Seong-Eun Yoon; Tae Jung Kwon; Jeong Rang Park; Seok-Jae Hwang; Eun-Ha Koh; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Projected morbidity and mortality from missed diagnoses of coronary artery disease in the United States.

Authors:  Joseph A Ladapo; Keith S Goldfeld; Pamela S Douglas
Journal:  Int J Cardiol       Date:  2015-05-08       Impact factor: 4.164

4.  The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.

Authors:  Eric S Ketchum; Kenneth Dickstein; John Kjekshus; Bertram Pitt; Meagan F Wong; David T Linker; Wayne C Levy
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09-11

Review 5.  Combining anticoagulation and antiplatelet drugs in coronary artery disease.

Authors:  Jyotsna Janardan; Harry Gibbs
Journal:  Aust Prescr       Date:  2018-08-01

6.  Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Authors:  Emmanuel Sorbets; Julien Labreuche; Tabassome Simon; Laurent Delorme; Nicolas Danchin; Pierre Amarenco; Shinya Goto; Christophe Meune; Kim A Eagle; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2014-03-09       Impact factor: 29.983

7.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.

Authors:  Dharam J Kumbhani; Ph Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Shinya Goto; E Magnus Ohman; Yedid Elbez; Piyamitr Sritara; Iris Baumgartner; Subhash Banerjee; Mark A Creager; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

8.  Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.

Authors:  J Antonio Gutierrez; Hillary Mulder; W Schuyler Jones; Frank W Rockhold; Iris Baumgartner; Jeffrey S Berger; Juuso I Blomster; F Gerry R Fowkes; Peter Held; Brian G Katona; Kenneth W Mahaffey; Lars Norgren; William R Hiatt; Manesh R Patel
Journal:  JAMA Netw Open       Date:  2018-11-02

9.  Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study.

Authors:  Dirk De Bacquer; Delphine De Smedt; Kornelia Kotseva; Catriona Jennings; David Wood; Lars Rydén; Viveca Gyberg; Bahira Shahim; Philippe Amouyel; Jan Bruthans; Almudena Castro Conde; Renata Cífková; Jaap W Deckers; Johan De Sutter; Mirza Dilic; Maryna Dolzhenko; Andrejs Erglis; Zlatko Fras; Dan Gaita; Nina Gotcheva; John Goudevenos; Peter Heuschmann; Aleksandras Laucevicius; Seppo Lehto; Dragan Lovic; Davor Miličić; David Moore; Evagoras Nicolaides; Raphael Oganov; Andrzej Pajak; Nana Pogosova; Zeljko Reiner; Martin Stagmo; Stefan Störk; Lale Tokgözoğlu; Dusko Vulic; Martin Wagner; Guy De Backer
Journal:  Eur J Epidemiol       Date:  2018-10-23       Impact factor: 8.082

10.  Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  J Dawn Abbott; Manuel S Lombardero; Gregory W Barsness; Ivan Pena-Sing; L Virginia Buitrón; Premranjan Singh; Gail Woodhead; Jean-Claude Tardif; Sheryl F Kelsey
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.